This review provides a comprehensive landscape of HGF/c-MET (hepatocyte growth factor
(HGF)/mesenchymal–epithelial transition factor (c-MET)) signaling pathway in cancers. First …

Head and neck cancer is the sixth most common cancer across the globe. This is generally
associated with tobacco and alcohol consumption. Cancer in the pharynx majorly arises …

Lung adenocarcinoma (LUAD) and squamous carcinoma (LUSC) are two major subtypes of
non-small cell lung cancer with distinct pathologic features and treatment paradigms. The …

Decrypting the dynamics of receptor dimerization on cell membranes bears great
importance in identifying the mechanisms regulating diverse cellular activities. In this regard …

Purpose: Although gefitinib prolonged the progression-free survival (PFS) of patients with
non–small cell lung cancer (NSCLC), unpredictable resistance limited its clinical efficacy …

The lung alveolus is lined with alveolar type 1 (AT1) and type 2 (AT2) epithelial cells. During
alveologenesis, increasing demand associated with expanding alveolar numbers is met by …

Advanced hepatocellular carcinoma (HCC) remains a formidable health challenge
worldwide, with a 5-year survival rate of 2.4% in patients with distant metastases. The …

Tyrosine kinase inhibitors (TKI) directed against MET have been recently approved to treat
advanced non-small cell lung cancer (NSCLC) harbouring activating MET mutations. This …

Background c-MET is a receptor tyrosine kinase which is classically activated by HGF to
activate its downstream signaling cascades such as MAPK, PI3K/Akt/mTOR, and STAT3 …

The MET receptor tyrosine kinase (RTK) and its cognate ligand hepatocyte growth factor
(HGF) comprise a signaling axis essential for development, wound healing and tissue …